Updating the physiology, exploration and disease relevance of complement factor H

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 397-404

  Buhe V ^a   Loisel, S ^a   Pers, J O ^a,b   Le Ster, K ^a   Berthou, C ^a,b   Youinou, Pierre ^a,b  

^a UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

Chronic inflammation; Complement regulation; Factor H; Homeostasis; Tissue injury

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT FACTOR H;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; BODY FLUID; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; COMPLEMENT INHIBITION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MISSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; TUMOR IMMUNITY;

EID: 77955358875     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300202     Document Type: Review

References (40)

1. Nilsson UR and Müller-Eberhard HJ. Isolation of beta1F-globulin from human serum and its characterization as the fifth component of complement. J Exp Med 1965; 125:1-16.
2. Rodriguez de Córdoba S, Diaz-Guillen MAand Heine-Suner D. An integrated map of the human regulator of complement activation (RCA) gene cluster on 1q32. Mol Immunol 1999; 36:803-8
3. Estaller C, Schwaeble W, Dierich M, Weiss EH. Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur J Immunol 1991; 21:799-02.
4. Díaz-Guillén MA, Rodríguez de Córdoba S, Heine-Suñer D. A radiation hybrid map of complement factor H and factor H-related genes. Immunogenetics 1999; 49:549-52.
5. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41:355-67.
6. Sharma AK, Pangburn MK. Identification of three 'physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci USA 1996; 93:10996-018.
7. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM, Gordon DL. Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998; 160:3342-8.
8. Mihlan M, Stippa S, Jozsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009; 16:1630-40.
9. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol 2008; 6:132-42.
10. Lu L, Ma Y, Zhang JR. Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA. J Biol Chem 2006; 281:15464-74.
11. Oliver MA, Rojo JM, Rodríguez de Córdoba S, Alberti S. Binding of complement regulatory proteins to group A Streptococcus. Vaccine 2008; 8:175-8.
12. Hartmann K, Corvey C, Skerka C, et al. Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol 2006; 61:1220-36.
13. Haupt K, Kraiczy P, Wallich R, Brade V, Skerka C, Zipfel PF. Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis 2007; 196:124-33.
14. Kenedy MR, Vuppala SR, Siegel C, Kraiczy P, Akins DR. CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. Infect Immun 2009; 77:2773-82.
15. Schneider MC, Prosser BE, Caesar JJ, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009; 458:890-3.
16. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 2007; 178:5991-8.
17. Wilczek E, Rzepko R, Nowis D, et al. The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 2008; 122:2030-7.
18. Cheng ZZ, Corey MJ, Pärepalo M, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem 2005; 51:856-63.
19. Schwertz R, Rother U, Anders D, Gretz N, Schärer K, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 2001; 12:166-72.
20. Paixao Paixão-Cavalcante D, Hanson S, Botto M, Cook HT, Pickering MC. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol 2009; 46:1942-50.
21. Schmidt BZ, Fowler NL, Hidvegi T, Perlmutter DH, Colten HR. Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency. J Biol Chem 1999; 274:11782-8.
22. Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007; 28:222-34.
23. Ferreira VP, Herbert AP, Cortés C, et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182:7009-18.
24. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008; 111:5307-15.
25. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115:379-87.
26. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110:1516-8.
27. Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25:136-44.
28. Machalińska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, Machaliński B. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 2009; 42:54-9.
29. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular degeneration. PLoS One 2008; 3:e2593.
30. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR, Chong NV. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 2007; 125:515-9.
31. Zetterberg M, Landgren S, Andersson ME, et al. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008; 147:720-6.
32. Hamilton G, Proitsi P, Williams J, O'Donovan M, Owen M, Powell J, Lovestone S. Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease. Neuromolecular Med 2007; 9:331-4.
33. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129:3042-50.
34. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008; 255:1712-20.
35. Zhou M, Larsen B. Factor H polymorphism, typing by isoelectrofocusing and immunoblotting: no association with rheumatoid arthritis. Hum Hered 1990; 40:55-7.
36. Friese MA, Hellwage J, Jokiranta TS, Meri S, Müller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121:406-15.
37. Friese MA, Manuelian T, Junnikkala S, Hellwage J, Meri S, Peter HH, Gordon DL, Eibel H, Zipfel PF. Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol 2003; 132:485-95.
38. Blom AM, Bergström F, Edey M, et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008; 180:6385-91.
39. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007; 17:341-6.
40. Heinen S, Sanchez-Corral P, Jackson MS, et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27:292-3.